By BullScreen Editorial Team 
Rossari Biotech Limited reported a strong set of Q4 results 2026, with robust growth in revenue and profitability driven by steady demand across its core specialty chemicals segments.
For the March quarter, revenue rose 18.2% year-on-year to ₹684.9 crore, while EBITDA increased 11.2% to ₹77.3 crore. Profit after tax (PAT) stood out, surging 33.7% to ₹46.0 crore, marking one of the strongest quarterly performances for the company.
The Q4 results 2026 capped a record-breaking fiscal year. For FY26, revenue from operations climbed 15.2% to ₹2,396.4 crore, while EBITDA grew 7.9% to ₹286.0 crore. PAT rose 9.4% to ₹149.2 crore, although EBITDA margin moderated to 11.9% from 12.7% a year earlier, reflecting cost pressures and ongoing optimization in select segments.
Rossari’s diversified business model continued to support growth momentum. The Home, Personal Care and Performance Chemicals (HPPC) segment remained the largest contributor, accounting for 77% of total revenue. Textile Specialty Chemicals (TSC) contributed 17%, while Animal Health and Nutrition (AHN) added 6%. Core B2B segments maintained healthy profitability, delivering an EBITDA margin of around 14% after excluding weaker institutional and B2C businesses.
From a longer-term perspective, the company has delivered a revenue CAGR of 25% between FY19 and FY26, underlining consistent execution. Export revenue also remained a key growth driver, rising at a 19% CAGR to ₹634 crore in FY26, as the company expanded its global footprint.
Operationally, Rossari strengthened its manufacturing and innovation capabilities during the year. Its subsidiary Unitop completed ethoxylation capacity expansion at Dahej, taking total capacity to 66,000 MTPA, while overall installed capacity reached 382,100 MTPA. The company also set up a new R&D facility in Navi Mumbai to accelerate product innovation.
International expansion remained a focus area, with new subsidiaries established in Thailand, Saudi Arabia, and Singapore, enhancing its global reach and customer access.
Despite margin moderation, stable return ratios with ROE and ROCE at 12% and a diversified customer base with the top 10 clients contributing only 13% of revenue indicate balanced growth.
The board has recommended a dividend of ₹0.50 per share for FY26, reflecting steady cash flows and a continued focus on shareholder returns.
| Category | Metric | Q4 FY26 | YoY Growth | FY26 (Annual) | YoY Growth |
|---|---|---|---|---|---|
| Revenue | Revenue from Operations | ₹684.9 Cr | +18.2% | ₹2,396.4 Cr | +15.2% |
| Profitability | EBITDA | ₹77.3 Cr | +11.2% | ₹286.0 Cr | +7.9% |
| Profit After Tax (PAT) | ₹46.0 Cr | +33.7% | ₹149.2 Cr | +9.4% | |
| EBITDA Margin | — | — | 11.9% | ↓ (from 12.7%) | |
| Business Segments | HPPC Contribution | — | — | 77% | — |
| TSC Contribution | — | — | 17% | — | |
| AHN Contribution | — | — | 6% | — | |
| Growth Metrics | Revenue CAGR (FY19–26) | — | — | 25% | — |
| Export Revenue | — | — | ₹634 Cr | CAGR 19% | |
| Customer Base | Top 10 Clients Contribution | — | — | 13% | — |
| Capacity & Operations | Total Installed Capacity | — | — | 382,100 MTPA | — |
| Ethoxylation Capacity (Dahej) | — | — | 66,000 MTPA | — | |
| Returns | ROE | — | — | 12.0% | — |
| ROCE | — | — | 12.0% | — | |
| Shareholder Return | Dividend | — | — | ₹0.50/share | — |
💰 Consistent returns with 12% ROE & ROCE
🚀 Strong Q4 results 2026 with 33.7% PAT growth
📈 Record annual revenue crossing ₹2,396 Cr
🌍 Exports at ₹634 Cr, strong global expansion
🏭 Capacity expanded to 382,100 MTPA
Source: https://www.bseindia.com/xml-data/corpfiling/AttachLive/940dde22-2876-411b-a8ed-a603f6e4c735.pdf